期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

炎症性肠病伴慢性肠道炎症的新治疗 被引量：2

New Therapy for Chronic Intestinal Inflammation in Inflammatory Bowel Disease
下载PDF
导出
摘要 肠道持续性慢性炎症是炎症性肠病(IBD)难以治愈的关键所在。造成肠道慢性炎症的核心机制是肠道血循环中淋巴细胞和血管内皮细胞的黏附和渗出。本文就主要黏附分子靶向抗黏附治疗的应用和临床地位作一简介。 Chronic persistent intestinal inflammation is the crucial factor of refractoriness of inflammatorty bowel disease（IBD）.The core mechanism of chronic intestinal inflammation is the adhesion and exudation of intestinal circulatory lymphocytes and endotheliual cells.The aim of this article was to review the clinical significance and use of the major anti-adhesion therapy targeting against adhesive molecules in the treatment of chronic intestinal inflammation in IBD.
作者 郑家驹
机构地区 江苏省苏州市立医院 南京医科大学附属苏州医院消化内科
出处 《胃肠病学》 2011年第8期506-508,共3页 Chinese Journal of Gastroenterology
关键词 炎症性肠病 治疗 整合素类 血管细胞黏附分子-1 Inflammatory Bowel Disease Therapy Integrins Vascular Cell Adhesion Molecule-1
分类号 R574 [医药卫生—消化系统]
  • 相关文献

参考文献18

  • 1Ghosh S, Panaccione R. Anti-adhesion molecule therapy for inflammatory bowel disease. Therap Adv Gastroenterol, 2010, 3 (4): 239-258.
  • 2Fiorino G, Correale C, Fries W, et al. Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease. Expert Rev Clin Immunol, 2010, 6 (4): 567-572.
  • 3Guidi L, Marzo M, Felice C, et al. New biological agents for the treatment of the "high risk" IBD patients. Eur Rev Med Pharmacol Sci, 2010, 14 (4): 342-346.
  • 4Scholmerich J. Evolving concepts in IBD therapy: What should be studied in the future? Dig Dis, 2010, 28 (3): 472-477.
  • 5Cornejo C J, Winn RK, Harlan JM. Anti-adhesion therapy. Adv Pharmacol, 1997, 39: 99-142.
  • 6Tilg H, Kaser A. Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease. Curr Opin Investig Drugs, 2010, 11 (11): 1295-1304.
  • 7Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology, 2009, 136 (4): 1182-1197.
  • 8Kucharzik T, Maaser C, Lugering A, et al. Recent understanding of IBD pathogenesis: implications for future therapies. Inflamm Bowel Dis, 2006, 12 (11): 1068-1083.
  • 9Sandborn W J, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology, 2002, 122 (6): 1592-1608.
  • 10Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology, 2007, 132 (1): 52-65.

二级参考文献29

  • 1Moss AC. Kim K J, Fernandez Becker N,et al. Impact of concomitant immunomodulator use on long term outcomes in patients receiving scheduled maintenance infliximab. Dig Dis Sci, 2009, Jun, 18. [Epub ahead of print].
  • 2Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximah in 614 patients with Crohn's disease: results from a single centre cohort. Gut, 2009,58:192-500.
  • 3Schnitzler F. Fidder H, Fcrrante M, et al. Mucosal healing predicts long term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis, 2009,15: 1295-1301.
  • 4Hyams JS, herer T, Griffilhs A, et al. I.ong term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm Bowel Dis. 2009,15:816-822.
  • 5Oussalah A, Babouri A, Chevaux JB, et al. Adalimumab for Crohn' s disease with intolerance or lost response to infliximab: a 3 year single centre experience. Aliment Pharmacol Ther, 2009,29:416-423.
  • 6Oussalah A, Laciotte C, Chevaux JB, et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther, 2008,28:966-972.
  • 7Caspersen S, Elkjaer M, Rus L, et al. Inflixirnab for inflammatory bowel disease in Denmark 1999 2005.-clinical outcome and follow up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol, 2008, 6:1212-1217.
  • 8Colombel JF, Loftus EV Jr, Tremaine WJ, el al. The safety profile of infliximab in patients with Crohn' s disease:the Mayo clinic experience in S00 patienls. Gastroenterology, 2004,126:19-31.
  • 9Russo EA, Iacucci M, Lindsay JO, et al. Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland. Eur J Gastroenterol Hepatol, 2009, Jun, 12. [Epub ahead of print].
  • 10Fidder H, Schnitzler F, Ferrante M, et al. I.ong-term safety of infliximab for the treatment of inflammatory bowel disease:a single-centre cohort study. Gut. 2009, 58:501-508.

共引文献3

同被引文献54

  • 1梁红亮,欧阳钦.炎症性肠病的生物治疗[J].医学新知,2004,14(4):255-258. 被引量：1
  • 2马锋振,马洪升.炎性肠病炎症过程中ICAM-1的表达及作用[J].胃肠病学和肝病学杂志,2005,14(4):419-421. 被引量：3
  • 3胡洁琼,陈春晓,厉有名.P选择素与炎症性肠病[J].国际消化病杂志,2007,27(2):92-93. 被引量：6
  • 4Meijer MJ, Mieremet-Ooms MA, van der Zon AM, van Duijn W, van Hogezand RA, Sier CF, Hommes DW, Lamers CB, Verspaget HW. Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype. Dig Liver Dis 2007; 39: 733-739.
  • 5Tolstanova G, Khomenko T, Deng X, Chen L, Tarnawski A, Ahluwalia A, Szabo S, Sandor Z. Neutralizing anti-vascular endothelial growth factor (VEGF) antibody reduces severity of experimental ulcerative colitis in rats: direct evidence for the pathogenic role of VEGF. J Pharmacol Exp Ther 2009; 328: 749-757.
  • 6Tolstanova G, Deng X, French SW, Lungo W, Paunovic B, Khomenko T, Ahluwalia A, Kaplan T, Dacosta-Iyer M, Tarnawski A, Szabo S, Sandor Z. Early endothelial damage and increased colonic vascular permeability in the development of experimental ulcerative colitis in rats and mice. Lab Invest 2012; 92: 9-21.
  • 7Sands BE, Kaplan GG. The role of TNFalpha in ulcerative colitis. J Clin Pharmacol 2007; 47: 930-941.
  • 8Kanaji N, Nelson A, Wang X, Sato T, Nakanishi M, Gunji Y, Basma H, Michalski J, Farid M, Rennard SI, Liu X. Differential Roles of JNK, ERK1/2, and p38 Mitogen-Activated Protein Kinases on Endothelial Cell Tissue Repair Functions in Response to Tumor Necrosis Factor-α. J Vasc Res 2012; 50: 145-156.
  • 9Danese S, Sans M, Scaldaferri F, Sgambato A, Rutella S, Cittadini A, Piqué JM, Panes J, Katz JA, Gasbarrini A, Fiocchi C. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol 2006; 176: 2617-2624.
  • 10Kumar P, Shen Q, Pivetti CD, Lee ES, Wu MH, Yuan SY. Molecular mechanisms of endothelial hyperpermeability: implications in inflammation. Expert Rev Mol Med 2009; 11: e19.

引证文献2

二级引证文献8

胃肠病学
2011年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部